HealthTree Logo
search more_vert
close
person Sign In / Create Account
GPRC5D and FCRH5 Targeted Therapies in Myeloma
GPRC5D and FCRH5 Targeted Therapies in Myeloma image
Relapsed/Refractory Myeloma
event Jun 15, 2023 / 01:00PM - 02:00PM EDT

Event Description

BCMA is a common target in new immunotherapies like CAR-T and certain bispecific antibodies. However, BCMA is not the only target of the myeloma cell that scientists can use to target the myeloma. Learn more about targets GPRC5D and FCRH5 in mutliple myeloma treatments.

Schedule & Agenda

The panelist Audrey Burton-Bethke
Introductions
1:00 PM
Audrey Burton-Bethke

Audrey introduces the agenda of the event and featured speaker Dr. Benjamin Diamond.

The panelist Benjamin Diamond, MD
Presentation
1:05 PM
Benjamin Diamond, MD

Dr. Diamond talks about targets GPRC5D and FCRH5 in mutliple myeloma treatments.

 

 

 

person
Questions and Answers
1:35 PM
Audience

Type your questions in the chat and we will answer them! 

Speakers & Moderators

The panelist Audrey Burton-Bethke
Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

Read Bio
The panelist Benjamin Diamond, MD
Benjamin Diamond, MD

Dr. Diamond is a hematologist/oncologist who specializes in the treatment of plasma cell disorders including monoclonal gammopathy of undetermined significance, smoldering myeloma, and multiple myeloma. His research interests include utilization of minimal residual disease (MRD)-guided approaches to clinical decision-making, maintenance therapy, and the genomics of multiple myeloma and secondary malignancies that occur in patients treated for multiple myeloma. He completed fellowship at Memorial Sloan Kettering Cancer Center, spending a year as chief fellow, and has just recently joined the myeloma group at Sylvester Comprehensive Cancer Center where he is now a member of the Myeloma Genomics Laboratory participating in translational research. Some of his current projects include: Characterizing the genomics and origin of therapy-related myelodysplastic syndromes and acute leukemias that develop post-melphalan treatment. An investigation of commonalities between rare structural variants seen in multiple myeloma at diagnosis and relapse; including real world data collected by HealthTree.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Sanofi
GSK
Regeneron
Bristol Myers Squibb

Follow Us

facebook instagram linkedin tiktok youtube